BioCryst slides on revised peramivir study, lack of funds
This article was originally published in Scrip
Executive Summary
Shares of BioCryst Pharmaceuticals fell as low as 10.4%, or 54 cents, on the NASDAQ 13 January after the firm said it would need additional funding from the US Biomedical Advanced Research & Development Authority (BARDA) to complete an ongoing, multicentre, randomised, double-blind, controlled study to evaluate the efficacy and safety of its intravenous antiviral peramivir. The news overshadowed more positive news of top-line data from another Phase III trial of the antiviral.